These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23141996)

  • 21. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients.
    Momeni A; Shahidi S; Seirafian S; Taheri S; Kheiri S
    Iran J Kidney Dis; 2010 Apr; 4(2):128-32. PubMed ID: 20404423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Another patient with a natural history of diabetic nephropathy: current situation and means of prevention.
    Heras M; Saiz A; Sánchez R; Fernández-Reyes MJ; Molina A; Rodríguez MA
    Nefrologia; 2011; 31(1):108-10. PubMed ID: 21270923
    [No Abstract]   [Full Text] [Related]  

  • 25. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
    Berl T
    Nephrol Dial Transplant; 2008 Aug; 23(8):2443-7. PubMed ID: 18467376
    [No Abstract]   [Full Text] [Related]  

  • 26. Treating diabetic nephropathy: unfinished success is not failure.
    Lewis J
    Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442
    [No Abstract]   [Full Text] [Related]  

  • 27. Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE.
    Lovshin JA; Cherney DZ
    Hypertens Res; 2014 Jan; 37(1):4-6. PubMed ID: 24026039
    [No Abstract]   [Full Text] [Related]  

  • 28. [Diabetic nephropathy and ACE inhibitors].
    Amann B
    Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
    Benck U; Haeckel S; Clorius JH; van der Woude FJ
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renoprotective effects of renin-angiotensin-system inhibitors.
    Parving HH; Rossing P
    Lancet; 2006 Mar; 367(9514):898-9; author reply 900-2. PubMed ID: 16546532
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacological prevention and treatment of diabetic nephropathy].
    Aitio ML
    Duodecim; 1993; 109(6):503-11. PubMed ID: 8062718
    [No Abstract]   [Full Text] [Related]  

  • 33. Endothelin A receptor antagonists in diabetic kidney disease.
    Georgianos PI; Agarwal R
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):338-344. PubMed ID: 28520568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
    Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
    Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of jiawei shenqi dihuang tang on the content of urinary protein in patients with diabetic nephropathy.
    Chen Y; Wei L; Ma M; Wu G; Zhang G; Wei Z
    J Tradit Chin Med; 1997 Sep; 17(3):184-6. PubMed ID: 10437191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
    Hollenberg NK
    J Hypertens Suppl; 1997 Dec; 15(7):S7-13. PubMed ID: 9532515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
    Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
    Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.